Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
- PMID: 29676359
- DOI: 10.4103/IJPM.IJPM_223_17
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
Abstract
Introduction: Over the past decade, we have moved on from a predominantly morphological and clinical classification of myeloproliferative neoplasms (MPN) to a more evolved classification that accounts for the molecular heterogeneity that is unique to this subgroup of hematological malignancies. This usually incorporates mutations in Janus kinase 2 (JAK2), MPL, and calreticulin (CALR) genes. In this manuscript, we report the frequency of these mutations in a cohort of Indian patients at a tertiary cancer center.
Materials and methods: One hundred and thirty cases of MPN were included in this study. These cases were diagnosed and classified based on the World Health Organization 2008 criteria. JAK2 and MPL mutations were detected using high sensitivity allele-specific polymerase chain reaction using fluorescent labeled primers followed by capillary electrophoresis. A subset of JAK2 and CALR mutations were assessed using a fragment length assay.
Results: Among the MPN, we had 20 cases of polycythemia vera (PV), 34 cases of essential thrombocythemia (ET), and 59 of myelofibrosis (MF). JAK2, MPL, and CALR mutations were mutually exclusive of each other. Seventeen cases were categorized as MPN unclassifiable (MPN-U). JAK2p.V617F and MPL mutations were present in 60% (78 of 130) and 5.3% (7 of 130) of all MPN. All the PV cases harbored the JAK2 p.V617F mutation. A total of 23.8% (31 of 130) of patients harbored CALR mutations. CALR exon 9 mutations were detected in 60.8% (14 of 23) and 50% (5 of 10) of JAK2 and MPL negative MF and ET cases, respectively. MPN-U cases included three JAK2 p.V617F positive, two MPL p.W515 L, and 12 CALR positive cases. Ten different types of CALR indels (8 deletions and 2 insertions) were detected of which Type I and Type II mutations were the most common, occurring at a frequency of 45.1% (14 of 31) and 22.5% (7 of 31), respectively.
Discussion and conclusion: We report frequencies of JAK2 p. V617F, MPL exon 10 and CALR mutations in 130 patients similar to those reported in western literature. These mutations carry not only diagnostic but also prognostic relevance.
Keywords: Calreticulin; Janus kinase 2; MPL; molecular genetics of myeloproliferative neoplasms in India.
Conflict of interest statement
There are no conflicts of interest
Similar articles
-
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):35-39. doi: 10.3760/cma.j.issn.0578-1426.2020.01.006. Zhonghua Nei Ke Za Zhi. 2020. PMID: 31887834 Chinese.
-
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?Asian Pac J Cancer Prev. 2016;17(3):923-6. doi: 10.7314/apjcp.2016.17.3.923. Asian Pac J Cancer Prev. 2016. PMID: 27039813 Review.
-
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV. Am J Clin Pathol. 2015. PMID: 26071474
-
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM. Am J Clin Pathol. 2015. PMID: 25873496
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.Colomb Med (Cali). 2023 Sep 30;54(3):e2035353. doi: 10.25100/cm.v54i3.5353. eCollection 2023 Jul-Sep. Colomb Med (Cali). 2023. PMID: 38111518 Free PMC article.
-
JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation.Pan Afr Med J. 2021 Jul 12;39:194. doi: 10.11604/pamj.2021.39.194.28307. eCollection 2021. Pan Afr Med J. 2021. PMID: 34603575 Free PMC article.
-
Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).Int J Environ Res Public Health. 2021 Jul 16;18(14):7582. doi: 10.3390/ijerph18147582. Int J Environ Res Public Health. 2021. PMID: 34300032 Free PMC article.
-
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):13-20. doi: 10.1016/j.hemonc.2021.03.002. Hematol Oncol Stem Cell Ther. 2022. PMID: 33789164 Free PMC article.
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Sci Rep. 2019 Dec 27;9(1):19838. doi: 10.1038/s41598-019-56236-x. Sci Rep. 2019. PMID: 31882869 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous